There is a great deal of noise, optimism, scepticism and hope around the use of AI in Life Sciences to drive better outcomes for patients and creating value for all stakeholders. This session will discuss how AI is being adopted to discover and target new medicines and how this can be balanced with effective regulation and IP protection in order to capture the value created

Agenda:
14.00  Registration & Networking
14.20  Welcome from the Chair
          Dave Gallagher, Partner, J A Kemp
14.25  Perspective 1 – AI as an enabler of systems biology approaches in precision medicine discovery
          Krzysztof Potempa, CEO Braincures
14.35  Perspective 2 – AI as an enabler of targeting the right patients to the right clinical trials and treatments
          Anne Bruinvels, CEO, Px Healthcare
14.45  Perspective 3 – AI as a challenge for regulators
          Isabel Teare, Senior Legal Advisor, Mills & Reeve 
14.55  AI is an enabler of innovation, but what can you patent?
          Stephen Hodson, Partner, J A Kemp
15.05 AI without high quality data is noise
          Femida Gawdry-Sridhar, CEO & Founder, Pulse Infoframe
15.15  Q&A Panel with the speakers
          Moderated by the Chair
•    Is AI being adopted equally across the bio-innovation journey?
•    Are research discovery patent claims more or less robust after AI?
•    Will inventors always be humans?
•    Will regulators always be humans?
•    Is AI going to lead to the next sliding doors moment in bio-innovation?
15.45  Closing Remarks
15.50  Networking over refreshments
16.30 Close

Registration: 
This event is free to attend, invite only and is particularly aimed at attendees from:
•    Life Science R&D companies
•    TechBio companies
•    Tech Transfer Offices/Academia
•    Investors
•    CRO/CDMO companies
To request an invitation, please email Tony Jones directly.